Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Synovitis Clear all
Completed Not applicable Interventional

Treatment for Sacroiliac Joint Pain Using Platelet-rich Plasma (PRP) Versus Steroid/Anesthetic

NCT05121961
View directory record Official record
Conditions
Low Back Pain, Sacroiliac Joint Synovitis
Interventions
Sacroiliac intra-articular injection
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions
nilotinib
Drug
Lead sponsor
Andrew J. Wagner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Santa Monica, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 1 Interventional Results available

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

NCT03291288
View directory record Official record
Conditions
Drug Interaction Potential
Interventions
Tolbutamide, Midazolam, Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 3 Interventional

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

NCT01213017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
certolizumab pegol
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Aventura, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

NCT04223635
View directory record Official record
Conditions
Moderate Hepatic Impairment
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

NCT04731675
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
Interventions
AMB-05X
Biological
Lead sponsor
AmMax Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Jul 23, 2026, 11:11 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Use of PET/CT to Evaluate Synovitis in the Temporomandibular Joint (TMJ)

NCT01471418
View directory record Official record
Conditions
Temporomandibular Joint, Conservative Treatment Therapy
Interventions
PET/CT with 18-FDG
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 1 Interventional

Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients

NCT00014794
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
15-O labeled water
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:11 AM EDT
Not listed No phase listed Observational

Elbow Arthroscopy Data Analysis

NCT03656185
View directory record Official record
Conditions
Osteoarthritis Elbow Left, Osteoarthritis Elbow Right, Lateral Epicondylitis, Left Elbow, Lateral Epicondylitis, Right Elbow, Plica Syndromes, Osteochondritis Dissecans
Interventions
Not listed
Lead sponsor
The Orthopaedic Research & Innovation Foundation
Other
Eligibility
Not listed
Enrollment
100 participants
Timeline
2018 – 2024
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Jul 23, 2026, 11:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Interventions
Pimicotinib(ABSK021), Placebo
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Beverly Hills, California • Durham, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 11:11 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT04192344
View directory record Official record
Conditions
Neoplasms, Tenosynovial Giant Cell Tumor
Interventions
ABSK021
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jul 23, 2026, 11:11 AM EDT
Terminated Phase 1 Interventional

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

NCT02673736
View directory record Official record
Conditions
Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
Interventions
PLX73086
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Jul 23, 2026, 11:11 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789
View directory record Official record
Conditions
TGCT
Interventions
Emactuzumab, Placebo
Drug
Lead sponsor
SynOx Therapeutics Limited
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Beverly Hills, California • Los Angeles, California • Overland Park, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 11:11 AM EDT
Terminated Phase 4 Interventional Results available

Lipogems Prospective Study

NCT03922490
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lipogems Device PLUS debridement, Debridement only
Device · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00425932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab
Biological
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Jul 23, 2026, 11:11 AM EDT
Terminated Phase 1 Interventional

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530
View directory record Official record
Conditions
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Interventions
PLX7486 TsOH
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

NCT01272830
View directory record Official record
Conditions
Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions
Placebo, Apatone®B
Drug
Lead sponsor
IC-MedTech Corporation
Industry
Eligibility
50 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 23, 2026, 11:11 AM EDT
Active, not recruiting Phase 3 Interventional

Dronabinol After Arthroscopic Surgery

NCT05335252
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Injuries, Meniscus Tear, Synovitis of Knee, Knee Ligament Injury, Chondral Injury of Left Knee, Chondral Injury of Right Knee, Loose Body Knee
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

NCT05349643
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
Interventions
AMB-05X
Biological
Lead sponsor
AmMax Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Sacramento, California • Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound

NCT02902562
View directory record Official record
Conditions
Synovitis, Rheumatoid Arthritis
Interventions
Contrast Enhanced Ultrasound (CEUS), Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 23, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

NCT00001677
View directory record Official record
Conditions
Arthritis, Rheumatoid, Synovitis
Interventions
Methotrexate, Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:11 AM EDT